BOSTON, May 04, 2023 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. CMPX, a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2023 financial results. “We are very pleased with the progress we are making toward our enrollment goals in both of our…Read More
Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update Compass Therapeutics NASDAQCMPX
